Iv%252525252525252525252525252525252525252525252520gentamicin

# IV Gentamicin ## Overview Gentamicin is an aminoglycoside antibiotic that acts via irreversible binding to the 30S ribosomal subunit, disrupting bacterial protein synthesis. It provides rapid bactericidal activity, primarily against aerobic Gram-negative bacilli (including *Pseudomonas aeruginosa*). ## Primary Indications * Serious Gram-negative infections (e.g., sepsis, complicated intra-abdominal infections, complicated UTIs, pneumonia). * Synergistic treatment for Gram-positive endocarditis (e.g., *Staphylococcus* or *Enterococcus* species). * Prophylaxis in specific surgical procedures. ## Adult Dosing * **Traditional Dosing:** 1.5–2.5 mg/kg IV every 8–12 hours based on renal function. * **Extended-Interval (Once-Daily) Dosing:** 5–7 mg/kg IV every 24 hours (dosage interval often adjusted based on nomograms like Hartford or Sawchuk-Zaske). * **Synergy for Endocarditis:** 1 mg/kg IV every 8 hours. * *Note: Dosing must be based on Ideal Body Weight (IBW) if total body weight is >20% above IBW.* ## Pediatric Dosing * **Term Neonates (0–7 days):** 4–5 mg/kg IV every 24–48 hours (adjust based on gestational age). * **Infants/Children:** 2.5 mg/kg IV every 8 hours, or 7.5 mg/kg/day divided every 8–24 hours depending on the infection site and susceptibility. * *Note: Always verify doses against institutional weight-based protocols, as pediatric kinetics differ significantly from adults.* ## Dose Adjustments * **Renal Impairment:** Mandatory. Dose reduction or interval extension is required based on CrCl. Follow local institutional protocols for specific nomogram utilization. * **Obesity:** If Actual Body Weight (ABW) > IBW, use Adjusted Body Weight (AdjBW) = IBW + 0.4(ABW - IBW). ## Contraindications * Hypersensitivity to gentamicin or any aminoglycoside, including history of serious toxic reactions (e.g., severe ototoxicity or nephrotoxicity) related to previous aminoglycoside use. ## Adverse Effects * **Nephrotoxicity:** Usually reversible; manifests as rising serum creatinine. * **Ototoxicity:** Often irreversible; presents as vestibular dysfunction (vertigo, ataxia) or auditory damage (tinnitus, high-frequency hearing loss). * **Neuromuscular Blockade:** Rare; risk increases in patients with myasthenia gravis or receiving concurrent paralytics. ## Key Drug Interactions * **Nephrotoxic Agents:** Increased risk of renal failure (e.g., Vancomycin, Amphotericin B, IV Contrast, NSAIDs, Cisplatin). * **Ototoxic Agents:** Additive risk of hearing loss (e.g., Loop diuretics like Furosemide). * **Neuromuscular Blockers:** Potential for prolonged respiratory paralysis. ## Monitoring * **Serum Concentrations:** Obtain random levels for traditional dosing (trough: 30 min before 3rd dose; peak: 30 min after 3rd dose). For extended-interval, use a specific nomogram (e.g., level 6–14 hours after the start of the first infusion). * **Renal Function:** Monitor serum creatinine and urine output daily. * **Auditory:** Baseline and periodic monitoring of hearing; assess for vertigo/tinnitus. ## Clinical Pearls * **Weight-based:** Always use IBW or AdjBW for dosing calculations; obesity leads to higher volume of distribution discrepancies. * **Post-Antibiotic Effect (PAE):** Gentamicin exhibits a significant PAE, allowing for clinical efficacy even when serum levels fall below the MIC. * **"Peak" vs. "MIC":** Aim for a peak-to-MIC ratio of at least 8:1 to 10:1 to ensure maximal killing efficacy. * **Fluid Status:** Ensure patient is well-hydrated to minimize the risk of drug accumulation in renal cortical tissue. *** *Disclaimer: This information is for educational purposes only. Gentamicin dosing must be verified against current institutional policies, patient-specific renal function, and updated prescribing literature before administration.*